Peter Evan Harwin
CIK 1663607 · last filed 2026-07-01
Peter Evan Harwin is a corporate insider who has filed 24 SEC Form 4 insider transactions across 10 companies since 2020. The most recent filing, for ORKA, was dated Jul 1, 2026. Across all open-market trades the lifetime net is −$1.47B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $369.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$369.67M
10
24
-$1.47B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORKA | Director | 1,131,954 | $90.45 | $102.39M | -$1.50B | 2 | 2026-07-01 |
| COGT | Director | — | $40.67 | — | $0 | 6 | 2026-06-11 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| ZBIO | Director | 2,209,025 | $32.29 | $71.33M | $24.03M | 2 | 2025-10-09 |
| JBIO | Director | — | $19.70 | — | $0 | 1 | 2025-05-01 |
| VRDN | Director | — | $19.51 | — | $0 | 5 | 2024-06-28 |
| APGE | Director | — | $134.17 | — | $0 | 1 | 2024-06-07 |
| DNTH | Director | 1,928,503 | $101.61 | $195.96M | $3.38M | 3 | 2023-10-03 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 1 | 2020-10-29 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | — | — | — | $0 | 1 | 2020-08-31 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-01 | ORKA | Mixed | — | -$1.50B | EDGAR |
| 2026-06-11 | COGT | Grant (A) | — | $0 | EDGAR |
| 2026-06-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-10-09 | ZBIO | Buy (P) | +1,264,876 | $24.03M | EDGAR |
| 2025-06-23 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-05-01 | JBIO | Grant (A) | — | $0 | EDGAR |
| 2024-11-21 | ORKA | Exer (M) | +640,000 | $0 | EDGAR |
| 2024-06-28 | VRDN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.